Bevacizumab biosimilar - Bionovis/The Instituto Vital Brazil

Drug Profile

Bevacizumab biosimilar - Bionovis/The Instituto Vital Brazil

Latest Information Update: 28 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionovis; The Instituto Vital Brazil
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast cancer; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 08 Jun 2015 Clinical trials in Breast cancer (Metastatic disease) in Brazil (IV) before June 2015
  • 08 Jun 2015 Clinical trials in Colorectal cancer (Metastatic disease) in Brazil (IV) before June 2015
  • 08 Jun 2015 Clinical trials in Non-small cell lung cancer in Brazil (IV) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top